BC
ESPR

Brinker Capital’s Esperion Therapeutics ESPR Stock Holding History

Brinker Capital’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		$322K Buy
+6,274
New +$263K 0.01% 805
2020
Q1 		– Sell
-7,743
Closed -$462K – 932
2019
Q4 		$462K Buy
+7,743
New +$348K 0.01% 735

Other funds holding ESPR

BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Brinker Capital's ESPR Position: Q2 2020 in Review

Brinker Capital opened a new position in Esperion Therapeutics (ESPR) in Q2 2020: 6,274 shares worth $322K. The stake represents 0.01% of the portfolio and ranks #805 among its holdings. This is a return to the name: Brinker Capital previously reported a position in ESPR as recently as Q4 2019.

Brinker Capital first reported a position in ESPR in Q4 2019 and has held it in 2 quarters since. The position peaked at $462K in Q4 2019. 182 funds tracked by Wall St. Rank hold ESPR as of Q2 2020.

  • Brinker Capital held 6,274 shares of Esperion Therapeutics worth $322K as of Q2 2020.
  • Esperion Therapeutics was a new Brinker Capital position in Q2 2020.
  • Esperion Therapeutics made up 0.01% of Brinker Capital's portfolio in Q2 2020, its #805 holding.
  • Brinker Capital first reported a position in Esperion Therapeutics in Q4 2019 and has held it in 2 quarters since.
  • Brinker Capital's Esperion Therapeutics position peaked at $462K in Q4 2019.
  • 182 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2020.

Based on Brinker Capital's 13F filing for Q2 2020, filed 30 Jul 2020.